Showing Metabocard for isopentenyl diphosphate (BASm0008100)

Common NameIsopentenyl diphosphate
DescriptionIsopentenyl pyrophosphate, IPP or isopentenyl diphosphate, is an intermediate in the HMG-CoA reductase pathway used by organisms in the biosynthesis of terpenes and terpenoids. IPP is formed from Mevalonate-5-pyrophosphate, in a reaction catalyzed by the enzyme mevalonate-5-pyrophosphate decarboxylase. (wikipedia).
Structure
Molecular FormulaC5H12O7P2
Average Mass246.09210
Monoisotopic Mass246.00583
IUPAC Name({hydroxy[(3-methylbut-3-en-1-yl)oxy]phosphoryl}oxy)phosphonic acid
Traditional Name[hydroxy(3-methylbut-3-en-1-yl)oxyphosphoryl]oxyphosphonic acid
CAS Registry Number358-71-4
SMILESC=C(C)CCOP(=O)([O-])OP(=O)([O-])[O-]
InChI IdentifierInChI=1S/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h1,3-4H2,2H3,(H,9,10)(H2,6,7,8)
InChI KeyNUHSROFQTUXZQQ-UHFFFAOYSA-N
CHEBI IDCHEBI:128769
HMDB IDHMDB0001347
Pathways
NameSMPDB/PathBank
Steroid Biosynthesis
Ibandronate Action Pathway
Simvastatin Action Pathway
Pravastatin Action Pathway
Rosuvastatin Action Pathway
Alendronate Action Pathway
Lovastatin Action Pathway
Zoledronate Action Pathway
Cerivastatin Action Pathway
Risedronate Action Pathway
Pamidronate Action Pathway
Fluvastatin Action Pathway
Atorvastatin Action Pathway
Hypercholesterolemia
Lysosomal Acid Lipase Deficiency (Wolman Disease)
Desmosterolosis
CHILD Syndrome
Chondrodysplasia Punctata II, X Linked Dominant (CDPX2)
Smith-Lemli-Opitz Syndrome (SLOS)
Cholesteryl ester storage disease
Hyper-IgD syndrome
Mevalonic aciduria
Wolman disease
StateSolid
Water Solubility6.69e+00 g/l
logP0.04
logS-1.57
pKa (Strongest Acidic)1.78
pKa (Strongest Basic)Not Available
Hydrogen Acceptor Count5
Hydrogen Donor Count3
Polar Surface Area113.29 Ų
Rotatable Bond Count6
Physiological Charge-2
Formal Charge0
Refractivity48.21 m³·mol⁻¹
Polarizability19.06

We require the use of cookies for essential features like storing your previously submitted BASys2 queries. Rejecting the usage of cookies will result in certain features being disabled. By clicking ACCEPT or continuing to use the website you are agreeing to our use of cookies.

ACCEPT